WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that the Company has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Chief Executive Officer Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating anti-cancer drug candidate. The presentation will take place at 2:30 pm ET on March 11, 2016 in room 402/403 at the Millennium Broadway hotel in New York City, NY.
